Viewing nowCombinationHanubiem 50/1000 mg Tablet
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.

MFDS item code 201503217 · Approved 2015.05.27 · Insurance code 647805530
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is suitable for helping blood sugar control in patients with type 2 diabetes, when used with dietary and exercise therapy. Sitagliptin and metformin work together to effectively improve blood sugar levels. Therefore, it is a good treatment option for those who need blood sugar management.
For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom administration is contraindicated). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral blood glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom administration is contraindicated).
This medication contains both sitagliptin and metformin. First, serious allergic reactions may occur during the use of this medication, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck occur, the medication should be stopped immediately and medical attention should be sought. Additionally, there is a risk of pancreatitis, which is an inflammation of the pancreas; therefore, sudden abdominal pain, nausea, or vomiting should be watched carefully, and if these symptoms occur, immediate consultation with a physician is required. Due to the metformin component, lactic acidosis, which is a rare but potentially life-threatening condition, may occur; symptoms such as muscle pain, shortness of breath, fatigue, or abdominal pain should lead to an immediate cessation of this medication and notification to healthcare personnel. This medication should not be taken by patients with severely impaired kidney function, severe infections or dehydration, heart failure, or conditions affecting kidney function such as acute myocardial infarction. Furthermore, if undergoing tests that involve using iodinated contrast agents, this medication should be discontinued for a period of time before and after the test, and should only be resumed once kidney function has recovered to normal. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. During use of this medication, irregular or insufficient food intake, intense exercise, or use of additional medications may increase the risk of hypoglycemia or lactic acidosis, so caution is advised. During treatment, side effects such as diarrhea, nausea, vomiting, abdominal pain, headaches, and upper respiratory infections may occur, and symptoms of hypoglycemia may also arise, so it is crucial to monitor blood sugar levels. In particular, when taking concurrently with insulin or sulfonylureas, there is an increased risk of hypoglycemia, thus dosage adjustments may be necessary according to a doctor's directive. Regular blood tests and kidney function tests should be conducted, and supplementation may be needed for potential Vitamin B12 deficiency. Excessive alcohol intake may increase the risk of side effects from this medication, so it is advisable to avoid it. In case of surgery, consultation should be initiated 48 hours prior to the procedure to stop taking this medication, and it should be resumed only after recovery of oral intake and confirmation of normal kidney function. If sudden joint pain or skin blistering occurs during treatment, immediate notification to a physician is required, and discontinuation of medication may be necessary if deemed appropriate. Finally, this medication is not recommended for use in children under 18 years of age, as safety and efficacy have not been established.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and kept at room temperature between 1 and 30 degrees Celsius. Storing it this way can help maintain the medication's effectiveness for a long time.
Red oval film-coated tablet
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Phosphate 62.04mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.